Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT)in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

Charles J. Rosser,Yosuke Hirasawa,Jared David Acoba,David Jon Tamura,Sumanta K. Pal,Jeffrey Huang,Mark C. Scholz,Tanya B. Dorff

Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT)in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

2020

Charles J. Rosser
Yosuke Hirasawa
Jared David Acoba
David Jon Tamura
Sumanta K. Pal
Jeffrey Huang
Mark C. Scholz
Tanya B. Dorff

e17564Background: Combining an immune checkpoint inhibitor with a tumor vaccine may leverage complementary mechanisms of action for treatment of mCRPC. Atezolizumab, a fully human anti–PD-L1 IgG1 a...

Keywords:

Castrate-resistant prostate cancer
Atezolizumab
Oncology
in patient
anti pd 1
Pathology
Internal medicine
Sipuleucel-T
Asymptomatic
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations